

<b>CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)</b> Applicant(s): <b>Molinier, et al.</b>			Docket No. <b>2003B114</b>	
Application No. <b>10/721,046</b>	Filing Date <b>November 24, 2003</b>	Examiner <b>Unassigned</b>	Group Art Unit <b>1764</b>	
Invention: <b>Selective Hydrogenation of Alkynes and/or Diolefins</b>			<b>RECEIVED CENTRAL FAX CENTER AUG 24 2004</b>	
<b>OFFICIAL</b>				
I hereby certify that this <u>Information Disclosure Statement, Form 1449 and 1 Reference (90 pgs.)</u> (Identify type of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-872-9306</u> ) on <u>August 24, 2004</u> (Date)				
<u>Tracy N. Keyes</u> (Typed or Printed Name of Person Signing Certificate) <u>Tracy N. Keyes</u> (Signature)				
Note: Each paper must have its own certificate of mailing.				

P18/REV02

**RECEIVED**  
**CENTRAL FAX CENTER**

AUG 24 2004

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b), 1.97(c), or 1.97(d)</b>			<b>Attny. Docket No. 2003B114</b>
<b>In Re Application of: Molinier et al.</b>			
<b>U.S. Serial No. 10/721,046</b>	<b>Filing Date November 24, 2003</b>	<b>Examiner Not Assigned</b>	<b>Group Art Unit 1764</b>

Address to:  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**OFFICIAL**

**37 CFR § 1.97(b)**

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of:

1. a Final Action under § 1.113,
2. a Notice of Allowance under § 1.311, or
3. an action that otherwise closes prosecution in the application,

and is accompanied by either:

- ☐ the fee as set forth in § 1.17(p), or  
☐ the following statement under § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

**37 CFR § 1.97(d)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after a Final Action under § 1.113, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution in the application, but before, or simultaneously with, the payment of the issue fee. Submitted herewith is the fee as set forth in § 1.17(p) and the following statement under 37 CFR § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicant hereby request consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith.

☒ Legible copies of the references are enclosed when required.

☐ This application is a:

- ☐ Continuation / Divisional,  
☐ Continuation-in-Part,

of U.S.S.N. \_\_\_\_\_. Copies of the cited references are ☐ enclosed; ☐ not enclosed. References are available in the parent application(s) if not enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account Number 05-1712. A duplicate copy of this form is enclosed.

August 24, 2004  
Date

Kelly A. Nowak

Kelly A. Nowak  
Registration No. 35,620  
ExxonMobil Chemical Company  
Law Technology  
P.O. Box 2149  
Baytown, Texas 77522-2149  
(281) 834-0341 Voice  
(281) 834-2495 Facsimile

FORM - 1449

SHEET 1 OF 1

<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO.		SERIAL NO.	
				2003B114		10/721,046	
				APPLICANT			
				Molinier et al.			
				FILING DATE		CRLP	
				11/24/03		1764	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,364,998	11/15/94	Sarrazin et al.	585	259	
	AB	5,877,363	03/02/99	Gildert et al.	585	260	
	AC	6,084,140	07/04/00	Kitamura et al.	585	260	
	AD	6,255,548	07/03/01	Didillon et al.	585	259	
	AE	2002/0068843	06/06/02	Dai et al.	585	260	
	AF						
	AG						
	AH						
	AI						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBL DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AJ	WO 2004/046076 (UK Appl. 2270866.6)	06/03/04	PCT	C07C	51/00	
	AK						
	AL						
OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages of Publication, Etc.)							
	AM						
	AN						
	AO						
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next comment to applicant							